

Benjamin Heidrich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2496841/publications.pdf>

Version: 2024-02-01

27
papers

1,306
citations

516215

16
h-index

552369

26
g-index

27
all docs

27
docs citations

27
times ranked

1701
citing authors

#	ARTICLE	IF	CITATIONS
1	Uncovering the trimethylamine-producing bacteria of the human gut microbiota. <i>Microbiome</i> , 2017, 5, 54.	4.9	336
2	Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. <i>Hepatology</i> , 2014, 60, 87-97.	3.6	234
3	Antiviral treatment and liver-related complications in hepatitis delta. <i>Hepatology</i> , 2017, 65, 414-425.	3.6	88
4	Establishment of a Novel Quantitative Hepatitis D Virus (HDV) RNA Assay Using the Cobas TaqMan Platform To Study HDV RNA Kinetics. <i>Journal of Clinical Microbiology</i> , 2010, 48, 2022-2029.	1.8	84
5	Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. <i>Liver International</i> , 2018, 38, 50-58.	1.9	72
6	Treatment Options for Hepatitis Delta Virus Infection. <i>Current Infectious Disease Reports</i> , 2013, 15, 31-38.	1.3	68
7	Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2342-2349.e2.	2.4	57
8	HBsAg-positive hepatitis delta: virological patterns and clinical long-term outcome. <i>Liver International</i> , 2012, 32, 1415-1425.	1.9	52
9	Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. <i>PLoS ONE</i> , 2014, 9, e101002.	1.1	50
10	Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1359-1368.	1.0	47
11	Non-invasive fibrosis score for hepatitis delta. <i>Liver International</i> , 2017, 37, 196-204.	1.9	42
12	Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. <i>United European Gastroenterology Journal</i> , 2018, 6, 1188-1198.	1.6	23
13	Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1384-1394.	1.0	19
14	Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. <i>Hepatology</i> , 2021, 74, 72-82.	3.6	19
15	Clinical characteristics of patients with liver cirrhosis and spontaneous portosystemic shunts detected by ultrasound in a tertiary care and transplantation centre. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1107-1113.	0.6	18
16	Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. <i>Biomedicines</i> , 2021, 9, 353.	1.4	18
17	Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. <i>PLoS ONE</i> , 2014, 9, e108751.	1.1	15
18	HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. <i>Hepatology Communications</i> , 2022, 6, 480-495.	2.0	15

#	ARTICLE	IF	CITATIONS
19	Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2016, 80, 1-7.	1.6	13
20	The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1033-1041.	0.6	13
21	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0128069.	1.1	5
22	Endoscopic vacuum assisted closure (E-VAC) of upper gastrointestinal leakages. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1-4.	0.6	5
23	Homeâ€based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 529-539.	1.9	5
24	The biliary microbiome in ischaemicâ€type biliary lesions can be shaped by stenting but is resilient to antibiotic treatment. <i>Liver International</i> , 2022, 42, 1070-1083.	1.9	4
25	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. <i>PLoS ONE</i> , 2015, 10, e0145622.	1.1	2
26	FRI-372-Next generation sequencing outperforms standard microbiological cultivation for detection of bacteria in the biliary tract in patients with ischemic type biliary lesions and/or anastomotic stricture. <i>Journal of Hepatology</i> , 2019, 70, e558.	1.8	2
27	Out of sight for the endoscopist? Gastrointestinal bleeding after aortic repair. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-8.	0.6	0